<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01429831</url>
  </required_header>
  <id_info>
    <org_study_id>031-TWB-1101i</org_study_id>
    <nct_id>NCT01429831</nct_id>
  </id_info>
  <brief_title>Aripiprazole for the Augmentation of Antidepressant Therapy</brief_title>
  <official_title>Aripiprazole for the Augmentation of Antidepressant Therapy: An Observational, Outpatients Study in Inadequate Responders Diagnosed With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiwan Otsuka Pharm. Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiwan Otsuka Pharm. Co., Ltd</source>
  <brief_summary>
    <textblock>
      The study aims to evaluate effectiveness and tolerability of aripiprazole augmentation in&#xD;
      outpatients with major depressive disorder who have had inadequate response to&#xD;
      antidepressants in Taiwan clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>17-Item Hamilton Depression Rating Scale (HAM-D17) score</measure>
    <time_frame>Week 1, 2, 4 and 6</time_frame>
    <description>Primary effectiveness endpoint:&#xD;
- Change from baseline in HAM-D17 score at Week 6&#xD;
Secondary effectiveness endpoints:&#xD;
Change from baseline in HAM-D17 score at Week 1, 2 and 4&#xD;
Response rate at Week 1, 2, 4 and 6&#xD;
- Response rate: decrease in HAM-D17 total score of at least 50%&#xD;
Remission rate at Week 1, 2, 4 and 6 - Remission rate: HAMD-17 score ≤ 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Severity (CGI-S) score</measure>
    <time_frame>Week 1, 2, 4 and 6</time_frame>
    <description>Change from baseline in CGI-S score at Week 1, 2, 4 and 6&#xD;
CGI-I score at Week 1, 2, 4 and 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Scale (SDS) total score</measure>
    <time_frame>Week 1, 2, 4 and 6</time_frame>
    <description>Change from baseline in SDS total score at Week 1, 2, 4 and 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>World Health Organization Quality of Life (WHOQOL-BREF) score</measure>
    <time_frame>Week 6</time_frame>
    <description>Change from baseline in WHOQOL-BREF score at Week 6</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>starting aripiprazole dose from 2-5mg/day, dose adjustment by every week, and maximum dose can up to 15mg/day. The duration is 6 weeks.</description>
    <arm_group_label>Aripiprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatients, either gender, 20-65 years of age&#xD;
&#xD;
          -  Patients diagnosed with major depressive disorder as defined by Diagnostic and&#xD;
             Statistical Manual of Mental Disorders (DSM-IV), who fulfill both the following&#xD;
             criteria:&#xD;
&#xD;
               -  Having at least one and no more than three inadequate responses of&#xD;
                  antidepressants&#xD;
&#xD;
               -  HAM-D17 score ≥ 14&#xD;
&#xD;
          -  Willing and able to comply with the study procedure and sign a written informed&#xD;
             consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant/lactating or planning to be pregnant&#xD;
&#xD;
          -  Presence of personality disorder cluster B (dramatic, emotional or erratic disorders)&#xD;
             or any psychotic symptomatology in the current depressive episode based on&#xD;
             Investigators judgment&#xD;
&#xD;
          -  History of organic mental disorder within 1 year prior to the screening visit&#xD;
&#xD;
          -  Acute risk of suicide attempts within 3 months prior to the initiation of study&#xD;
             treatment (HAM D-17 score item 3 ≥ 3)&#xD;
&#xD;
          -  Electroconvulsive therapy (ECT) for current episode&#xD;
&#xD;
          -  Past exposure to aripiprazole treatment or any investigational product (including drug&#xD;
             and invasive medical device) within 4 weeks prior to the initiation of study treatment&#xD;
&#xD;
          -  History of substance / alcohol abuse within 1 year prior to the screening visit&#xD;
&#xD;
          -  Patient with any medical or psychotic feature, including the presence of significant&#xD;
             abnormal laboratory values, which is considered not suitable for this study by&#xD;
             Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Te-Jen Lai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung Shan Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>September 1, 2011</study_first_submitted>
  <study_first_submitted_qc>September 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2011</study_first_posted>
  <last_update_submitted>May 19, 2014</last_update_submitted>
  <last_update_submitted_qc>May 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

